-
1
-
-
0030593031
-
Toward an understanding of the correlates of protective immunity to HIV infection
-
1. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection [see comments]. Science 1996; 271:324-8.
-
(1996)
Science
, vol.271
, pp. 324-328
-
-
Haynes, B.F.1
Pantaleo, G.2
Fauci, A.S.3
-
3
-
-
17344365609
-
Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
-
AIDS Vaccine Evaluation Group
-
3. Corey L, McElrath MJ, Weinhold K, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:301-9.
-
(1998)
J Infect Dis
, vol.177
, pp. 301-309
-
-
Corey, L.1
McElrath, M.J.2
Weinhold, K.3
-
4
-
-
0029054368
-
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
-
4. Egan MA, Pavlat WA, Tartaglia J, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995;171: 1623-7.
-
(1995)
J Infect Dis
, vol.171
, pp. 1623-1627
-
-
Egan, M.A.1
Pavlat, W.A.2
Tartaglia, J.3
-
5
-
-
0028986509
-
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/ LAI)
-
The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA [published erratum appears in AIDS Res Hum Retroviruses 1995;11:875]
-
5. Pialoux G, Excler JL, Riviere Y, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/ LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA [published erratum appears in AIDS Res Hum Retroviruses 1995;11:875]. AIDS Res Hum Retroviruses 1995;11:373-81.
-
(1995)
AIDS Res Hum Retroviruses
, vol.11
, pp. 373-381
-
-
Pialoux, G.1
Excler, J.L.2
Riviere, Y.3
-
6
-
-
0026492569
-
+ cytolytic t lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines
-
+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531-42.
-
(1992)
J Exp Med
, vol.176
, pp. 1531-1542
-
-
Hammond, S.A.1
Bollinger, R.C.2
Stanhope, P.E.3
-
8
-
-
0029160880
-
A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees
-
8. Perales MA, Schwartz DH, Fabry JA, Lieberman J. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:27-35.
-
(1995)
J Acquir Immune Defic Syndr Hum Retrovirol
, vol.10
, pp. 27-35
-
-
Perales, M.A.1
Schwartz, D.H.2
Fabry, J.A.3
Lieberman, J.4
-
9
-
-
19244362119
-
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a rccombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160
-
9. Fleury B, Janvier G, Pialoux G, et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a rccombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174: 734-8.
-
(1996)
J Infect Dis
, vol.174
, pp. 734-738
-
-
Fleury, B.1
Janvier, G.2
Pialoux, G.3
-
10
-
-
0031039054
-
HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation
-
10. McElrath MJ, Siliciano RF, Weinhold KJ. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res Hum Retroviruses 1997;13:211-6.
-
(1997)
AIDS Res Hum Retroviruses
, vol.13
, pp. 211-216
-
-
McElrath, M.J.1
Siliciano, R.F.2
Weinhold, K.J.3
-
11
-
-
7144259087
-
Immune responses to human immunodenciency virus (HIV) type 1 induced by canarypox expressing HIV-IMN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
-
NIAID AIDS Vaccine Evaluation Group
-
11. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodenciency virus (HIV) type 1 induced by canarypox expressing HIV-IMN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-46.
-
(1998)
J Infect Dis
, vol.177
, pp. 1230-1246
-
-
Clements-Mann, M.L.1
Weinhold, K.2
Matthews, T.J.3
-
12
-
-
7844229165
-
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 sf-2 recombinant vaccines in uninfected volunteers
-
NIAID AIDS Vaccine Evaluation Group
-
12. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998;12:2407-15.
-
(1998)
AIDS
, vol.12
, pp. 2407-2415
-
-
Belshe, R.B.1
Gorse, G.J.2
Mulligan, M.J.3
-
14
-
-
0030869489
-
Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-I altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides
-
14. Sewell AK, Harcourt GC, Goulder PJ, Price DA, Phillips RE. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-I altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur J Immunol 1997;27:2323-9.
-
(1997)
Eur J Immunol
, vol.27
, pp. 2323-2329
-
-
Sewell, A.K.1
Harcourt, G.C.2
Goulder, P.J.3
Price, D.A.4
Phillips, R.E.5
-
15
-
-
0029046706
-
Immunogenic HIV variant peptides that bind to HLA-BS can fail to stimulate cytotoxic T lymphocyte responses
-
15. McAdam S, Klenerman P, Tussey L, et al. Immunogenic HIV variant peptides that bind to HLA-BS can fail to stimulate cytotoxic T lymphocyte responses. J Immunol 1995;155:2729-36.
-
(1995)
J Immunol
, vol.155
, pp. 2729-2736
-
-
McAdam, S.1
Klenerman, P.2
Tussey, L.3
-
16
-
-
16944365445
-
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
-
16. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus [see comments]. Nat Med 1997;3:205-11.
-
(1997)
Nat Med
, vol.3
, pp. 205-211
-
-
Borrow, P.1
Lewicki, H.2
Wei, X.3
-
17
-
-
0029006397
-
The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus
-
17. Klenerman P, Meier UC, Phillips RE, McMichael AJ. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur J Immunol 1995;25: 1927-31.
-
(1995)
Eur J Immunol
, vol.25
, pp. 1927-1931
-
-
Klenerman, P.1
Meier, U.C.2
Phillips, R.E.3
McMichael, A.J.4
-
18
-
-
0027462887
-
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
-
18. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993;90:1882-6.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 1882-1886
-
-
Cooney, E.L.1
McElrath, M.J.2
Corey, L.3
-
19
-
-
0027404328
-
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults
-
The NIAID AIDS Vaccine Clinical Trials Network
-
19. Graham BS, Matthews TJ, Belshe RB, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis 1993; 167:533-7.
-
(1993)
J Infect Dis
, vol.167
, pp. 533-537
-
-
Graham, B.S.1
Matthews, T.J.2
Belshe, R.B.3
-
20
-
-
0027968518
-
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus
-
The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network
-
20. Graham BS, Gorse GJ, Schwartz DH, et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. J Infect Dis 1994;170:782-6.
-
(1994)
J Infect Dis
, vol.170
, pp. 782-786
-
-
Graham, B.S.1
Gorse, G.J.2
Schwartz, D.H.3
-
22
-
-
0023927549
-
+ T helper cell function in vivo: Differential requirement for induction of antiviral cytotoxic T-cell and antibody responses
-
+ T helper cell function in vivo: differential requirement for induction of antiviral cytotoxic T-cell and antibody responses. J Virol 1988;62:2102-6.
-
(1988)
J Virol
, vol.62
, pp. 2102-2106
-
-
Ahmed, R.1
Butler, L.D.2
Bhatti, L.3
-
23
-
-
0031204408
-
The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection
-
23. Livingston BD, Crimi C, Grey H, et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997;159:1383-92.
-
(1997)
J Immunol
, vol.159
, pp. 1383-1392
-
-
Livingston, B.D.1
Crimi, C.2
Grey, H.3
-
24
-
-
0029966723
-
Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides
-
24. Sauzet JP, Gras-Masse H, Guillet JG, Gomard E. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides. Int Immunol 1996;8:457-65.
-
(1996)
Int Immunol
, vol.8
, pp. 457-465
-
-
Sauzet, J.P.1
Gras-Masse, H.2
Guillet, J.G.3
Gomard, E.4
-
25
-
-
0025817991
-
Normal development and function of CD8' cells but markedly decreased helper cell activity in mice lacking CD4
-
25. Rahemtulla A, Fung-Leung WP, Schilham MW, et al. Normal development and function of CD8' cells but markedly decreased helper cell activity in mice lacking CD4. Nature 1991;353:180-4.
-
(1991)
Nature
, vol.353
, pp. 180-184
-
-
Rahemtulla, A.1
Fung-Leung, W.P.2
Schilham, M.W.3
-
26
-
-
0030986358
-
A critical role for neutralizing-antibody-producing B cells, CD4(') T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: Implications for adoptive immunotherapy of virus carriers
-
26. Planz O, Ehl S, Furrer E, et al. A critical role for neutralizing-antibody-producing B cells, CD4(') T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc Natl Acad Sci USA 1997;94:6874-9.
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, pp. 6874-6879
-
-
Planz, O.1
Ehl, S.2
Furrer, E.3
-
27
-
-
0018581317
-
The effect of specific antibody on the generation of cytotoxic T lymphocytes and the recovery of mice from influenza virus infection
-
27. Yap KL, Ada GL. The effect of specific antibody on the generation of cytotoxic T lymphocytes and the recovery of mice from influenza virus infection. Scand J Immunol 1979;10:325-32.
-
(1979)
Scand J Immunol
, vol.10
, pp. 325-332
-
-
Yap, K.L.1
Ada, G.L.2
-
28
-
-
0022468614
-
Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse
-
28. Bangham CR. Passively acquired antibodies to respiratory syncytial virus impair the secondary cytotoxic T-cell response in the neonatal mouse. Immunology 1986;59:37-41.
-
(1986)
Immunology
, vol.59
, pp. 37-41
-
-
Bangham, C.R.1
-
29
-
-
0029197894
-
The safety and use of canarypox vectored vaccines
-
29. Plotkin SA, Cadoz M, Meignier B, et al. The safety and use of canarypox vectored vaccines. Dev Biol Stand 1995;84:165-70.
-
(1995)
Dev Biol Stand
, vol.84
, pp. 165-170
-
-
Plotkin, S.A.1
Cadoz, M.2
Meignier, B.3
-
30
-
-
0026762697
-
Immunisation with canarypox virus expressing rabies glycoprotein
-
30. Cadoz M, Strady A, Meignier B, et al. Immunisation with canarypox virus expressing rabies glycoprotein (see comments). Lancet 1992;339:1429-32.
-
(1992)
Lancet
, vol.339
, pp. 1429-1432
-
-
Cadoz, M.1
Strady, A.2
Meignier, B.3
-
31
-
-
0029957222
-
Applications of pox virus vectors to vaccination: An update
-
31. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996;93:11349-53.
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 11349-11353
-
-
Paoletti, E.1
-
32
-
-
0029947256
-
Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative pox-virus vector system
-
32. Fries LF, Tartaglia J, Taylor J, et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative pox-virus vector system. Vaccine 1996;14:428-34.
-
(1996)
Vaccine
, vol.14
, pp. 428-434
-
-
Fries, L.F.1
Tartaglia, J.2
Taylor, J.3
-
33
-
-
0028997136
-
Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species
-
33. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995;13:539-49.
-
(1995)
Vaccine
, vol.13
, pp. 539-549
-
-
Taylor, J.1
Meignier, B.2
Tartaglia, J.3
-
34
-
-
0027988552
-
Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non HIV-infected human volunteers
-
34. Kahn JO, Sinangil F, Baenziger J, et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non HIV-infected human volunteers. J Infect Dis 1994;170:1288-91.
-
(1994)
J Infect Dis
, vol.170
, pp. 1288-1291
-
-
Kahn, J.O.1
Sinangil, F.2
Baenziger, J.3
-
35
-
-
9244255773
-
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59
-
NIAID AIDS Vaccine Evaluation Group
-
35. Keefer MC, Graham BS, McElrath MJ, et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1996;12:683-93.
-
(1996)
AIDS Res Hum Retroviruses
, vol.12
, pp. 683-693
-
-
Keefer, M.C.1
Graham, B.S.2
McElrath, M.J.3
-
36
-
-
0030967937
-
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group
-
36. Keefer MC, Wolff M, Gorse GJ, et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1997;13: 1163-77.
-
(1997)
AIDS Res Hum Retroviruses
, vol.13
, pp. 1163-1177
-
-
Keefer, M.C.1
Wolff, M.2
Gorse, G.J.3
-
37
-
-
0027178289
-
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
-
37. Schwartz DH, Gorse G, Clements ML, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
-
(1993)
Lancet
, vol.342
, pp. 69-73
-
-
Schwartz, D.H.1
Gorse, G.2
Clements, M.L.3
-
38
-
-
0030764685
-
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection
-
38. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997;176:924-32.
-
(1997)
J Infect Dis
, vol.176
, pp. 924-932
-
-
Pilgrim, A.K.1
Pantaleo, G.2
Cohen, O.J.3
-
39
-
-
0013680466
-
+ CTL induced in AIDS Vaccine Evaluation Group phase 1 trials using canarypox vectors (AL-VAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost
-
Geneva
-
+ CTL induced in AIDS Vaccine Evaluation Group phase 1 trials using canarypox vectors (AL-VAC) encoding multiple HIV gene products (vCP125, vCP205, vCP300) given with or without subunit boost. 12th World Conference AIDS, Geneva, 1998.
-
(1998)
12th World Conference AIDS
-
-
Evans, T.G.1
Corey, L.2
Clements-Mann, M.L.3
-
40
-
-
0004510030
-
The HLA-class I-restricted CTL response in HIV-1 infection; identification of optimal epitopes
-
Los Alamos National Laboratory, Los Alamos, NM: IV-1-IV-8
-
40. Brander C, Walker BD. The HLA-class I-restricted CTL response in HIV-1 infection; identification of optimal epitopes. HIV Molecular Immunology Database, 1995; Los Alamos National Laboratory, Los Alamos, NM: IV-1-IV-8.
-
(1995)
HIV Molecular Immunology Database
-
-
Brander, C.1
Walker, B.D.2
-
41
-
-
0013664814
-
Frequency and duration of HIV-1 specific cytolytic reactivities elicited in response to candidate AIDS vaccines
-
Park City, UT
-
41. Ferrari G, Humphrey W, Corr K, et al. Frequency and duration of HIV-1 specific cytolytic reactivities elicited in response to candidate AIDS vaccines. Keystone Symposium on HIV Pathogenesis and Treatment, Park City, UT, 1998.
-
(1998)
Keystone Symposium on HIV Pathogenesis and Treatment
-
-
Ferrari, G.1
Humphrey, W.2
Corr, K.3
-
42
-
-
19144365910
-
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
-
The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group
-
42. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996;173:340-8.
-
(1996)
J Infect Dis
, vol.173
, pp. 340-348
-
-
Mascola, J.R.1
Snyder, S.W.2
Weislow, O.S.3
-
43
-
-
16944367422
-
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
-
43. Zolla-Pazner S, Alving C, Bclshe R, et al. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines [see comments]. J Infect Dis 1997;175:764-74.
-
(1997)
J Infect Dis
, vol.175
, pp. 764-774
-
-
Zolla-Pazner, S.1
Alving, C.2
Bclshe, R.3
-
44
-
-
0030586434
-
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. A randomized, double-blind trial
-
NIAID AIDS Vaccine Evaluation Group
-
44. Graham BS, Keefer MC, McElrath MJ, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996;125:270-9.
-
(1996)
Ann Intern Med
, vol.125
, pp. 270-279
-
-
Graham, B.S.1
Keefer, M.C.2
McElrath, M.J.3
-
45
-
-
0031037693
-
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
-
45. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Prat Natl Acad Sci USA 1997;94:1396-401.
-
(1997)
Prat Natl Acad Sci USA
, vol.94
, pp. 1396-1401
-
-
Ferrari, G.1
Humphrey, W.2
McElrath, M.J.3
-
46
-
-
0029847966
-
+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes
-
+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J Virol 1996;70:8165-8.
-
(1996)
J Virol
, vol.70
, pp. 8165-8168
-
-
Posavad, C.M.1
Koelle, D.M.2
Corey, L.3
-
47
-
-
0030931689
-
Rapid effector function in CD8' memory T cells
-
47. Lalvani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. Rapid effector function in CD8' memory T cells. J Exp Med 1997;186: 859-65.
-
(1997)
J Exp Med
, vol.186
, pp. 859-865
-
-
Lalvani, A.1
Brookes, R.2
Hambleton, S.3
Britton, W.J.4
Hill, A.V.5
McMichael, A.J.6
-
48
-
-
0029793618
-
Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes
-
48. Yang OO, Kalams SA, Rosenzweig M, et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J Virol 1996;70:5799-806.
-
(1996)
J Virol
, vol.70
, pp. 5799-5806
-
-
Yang, O.O.1
Kalams, S.A.2
Rosenzweig, M.3
-
49
-
-
0032556872
-
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
-
49. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;191:397-401.
-
(1998)
Nature
, vol.191
, pp. 397-401
-
-
Collins, K.L.1
Chen, B.K.2
Kalams, S.A.3
Walker, B.D.4
Baltimore, D.5
|